No profile data available.
Aeon Biopharma, Inc. (AEON) is a healthcare company in the brain and nerve treatment drugs industry, based in Irvine, United States, with about 8 full-time employees.
In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $13.77 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
$13.77 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Quantum BioPharma Ltd. (QNTM), ProMIS Neurosciences, Inc. (PMN), Athira Pharma, Inc. (ATHA), BioVie Inc. (BIVI).